ERBB2 and non-small cell lung carcinoma: The DESTINY-Lung01 and DESTINY-Lung02 trials demonstrated a high objective response rate and durable clinical benefit, leading to its FDA approval for HER2-mutated metastatic NSCLC [51,59].